Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer
Public ClinicalTrials.gov record NCT02481830. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First Line Chemotherapy (CheckMate 331: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 331)
Study identification
- NCT ID
- NCT02481830
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Enrollment
- 569 participants
Conditions and interventions
Conditions
Interventions
- Nivolumab Drug
- Topotecan Drug
- Amrubicin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 13, 2015
- Primary completion
- Aug 16, 2018
- Completion
- Aug 29, 2022
- Last update posted
- Jul 26, 2023
2015 – 2022
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0065 | Little Rock | Arkansas | 72205 | — |
| Local Institution - 0024 | New Haven | Connecticut | 06520 | — |
| Local Institution - 0018 | Atlanta | Georgia | 30322 | — |
| Local Institution - 0056 | St Louis | Missouri | 63110 | — |
| Local Institution - 0088 | Lincoln | Nebraska | 68506 | — |
| Local Institution - 0173 | Johnson City | New York | 13790 | — |
| Local Institution - 0001 | Durham | North Carolina | 27710 | — |
| Local Institution - 0090 | Cleveland | Ohio | 44106 | — |
| Local Institution - 0002 | Bethlehem | Pennsylvania | 18015 | — |
| Local Institution - 0057 | Lancaster | Pennsylvania | 17604 | — |
| Local Institution - 0053 | Philadelphia | Pennsylvania | 19111-2412 | — |
| Local Institution - 0089 | Nashville | Tennessee | 37203 | — |
| Local Institution - 0009 | Nashville | Tennessee | 37232 | — |
| Local Institution - 0070 | Kennewick | Washington | 99336 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 137 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02481830, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 26, 2023 · Synced Jul 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02481830 live on ClinicalTrials.gov.